Description
Awiqli (Insulin Icodec) is a once-weekly basal insulin analog designed to provide long-acting glycemic control in individuals with diabetes mellitus. Developed using advanced protein engineering, Awiqli offers a stable and prolonged glucose-lowering effect by forming a subcutaneous depot that gradually releases insulin. Its extended half-life supports consistent blood sugar management with only one injection per week, offering convenience and adherence support for patients requiring basal insulin therapy. Individuals seeking to buy Awiqli benefit from its reduced injection frequency compared to traditional daily insulins. This long-acting formulation is indicated for adults with type 1 or type 2 diabetes who require basal insulin for glycemic control.
| Fact Table |
| Formula | C267H404N64O76S6 |
| License | FDA approved (March 2024) |
| Bioavailability | ~80% (subcutaneous) |
| Legal status | Prescription only (Rx) |
| Chemical Name | Insulin icodec |
| Elimination half-life | ~196 hours (approx. 8 days) |
| Dosage (Strength) | 700 units/mL in pre-filled pens |
| Pregnancy | Consult healthcare provider |
| Brands | Awiqli |
| Protein binding | Low; similar to human insulin |
| PubChem CID | 162199366 |
| MedlinePlus | Not assigned |
| ChEBI | Not listed |
| ATC code | A10AE09 |
| DrugBank | DB16612 |
| KEGG | D12623 |
| Routes of administration | Subcutaneous injection |
Directions
Awiqli should be administered once weekly by subcutaneous injection into the thigh, upper arm, or abdomen, on the same day each week. Initiation and titration must be guided by a healthcare provider based on individual insulin requirements and glycemic response. In patients switching from another basal insulin, an appropriate washout period or overlap may be recommended. Regular blood glucose monitoring is advised to assess efficacy and adjust dosage accordingly. Patients using Awiqli insulin should be trained on proper injection technique to ensure consistent absorption.
Ingredients
Each mL of Awiqli contains 70 units of insulin icodec, a modified human insulin analog, in a clear, colorless solution. Inactive components include glycerol, phenol, zinc chloride, and water for injection. The formulation does not contain preservatives beyond those listed.
Cautions
Close medical supervision is required when initiating Awiqli, particularly in patients with hepatic or renal impairment, or when transferring from another insulin regimen. As with all insulins, dose adjustments may be needed in response to changes in physical activity, meal patterns, or concomitant illness. Hypoglycemia remains the most common adverse event and should be managed promptly. Do not interchange with other insulins without medical guidance. The Awiqli price may vary by provider, and cost considerations should be discussed with a healthcare professional or pharmacy service.
Contraindications
Awiqli is contraindicated in individuals with hypersensitivity to insulin icodec or any of the excipients in the formulation. It must not be used during episodes of hypoglycemia. This medication is not intended for use in diabetic ketoacidosis or in pediatric patients, as safety and efficacy in these populations have not been established.
Side Effects
Common and potential side effects of Awiqli include:
- Hypoglycemia (low blood sugar)
- Injection site reactions (e.g., redness, swelling, itching)
- Weight gain
- Lipodystrophy (fat redistribution)
- Allergic reactions (rare but may be severe)
Serious adverse effects should be reported immediately to a healthcare provider.
Frequently Asked Questions about Awiqli (insulin icodec)
What is Awiqli (insulin icodec)?
Awiqli is a once-weekly basal insulin for adults with diabetes. It's the first FDA-approved once-weekly insulin, offering an alternative to daily injections.
How is Awiqli different from traditional insulin?
Unlike daily insulins, Awiqli has a significantly longer half-life that allows for once-weekly dosing. It maintains steady blood glucose control throughout the week.
Who is Awiqli suitable for?
Awiqli is approved for adults with type 1 or type 2 diabetes who need basal insulin therapy. It may be particularly beneficial for those who struggle with daily injection adherence.
How do I transition from daily insulin to once-weekly Awiqli?
Transitioning requires careful monitoring and dose adjustment. Your healthcare provider will create a personalized switching plan based on your current insulin regimen.
What are the common side effects of Awiqli?
Common side effects include hypoglycemia (low blood sugar), injection site reactions, and weight gain, similar to other insulin products.
How should Awiqli be stored?
Unopened Awiqli pens should be refrigerated (36-46°F). After first use, pens can be kept at room temperature (below 86°F) for up to 28 days.
Can I take Awiqli with other diabetes medications?
Yes, Awiqli can be used alongside oral diabetes medications or mealtime insulins as prescribed by your healthcare provider.
What if I miss an Awiqli dose?
If you miss a dose, administer it as soon as possible within 3 days of the scheduled dose. If more than 3 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day.
How is blood glucose monitoring different with Awiqli?
While you'll still need to monitor your blood glucose regularly, patterns may be more stable throughout the week. Your healthcare provider will advise on monitoring frequency.
IMPORTANT NOTE:
The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.
Product Code : 15328
Prescription Required